This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechnology: Archive
Here's Why You Should Add ARQT Stock to Your Portfolio Now
by Zacks Equity Research
Arcutis raises its 2026 revenue guidance as Zoryve gains momentum, expands into younger patients and advances potential new indications.
ARQTNegative Net Change ALDXNegative Net Change ACIUNegative Net Change PGENNegative Net Change
biotechnology
Gilead Wins FDA Nod for Bixlenvo in Adults Living With HIV Infection
by Zacks Equity Research
GILD wins FDA approval for Bixlenvo, a once-daily HIV regimen offering a smaller single-tablet option for patients on complex therapies.
GILDNegative Net Change ALDXNegative Net Change ACIUNegative Net Change PGENNegative Net Change
biotechnology biotechs medical pharmaceuticals
Microsoft (MSFT) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
MSFTPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH
by Zacks Equity Research
UTHR's ralinepag NDA receives FDA acceptance, with a 2027 decision ahead as positive phase III data support its PAH potential.
UTHRNegative Net Change MNKDNegative Net Change ACIUNegative Net Change PGENNegative Net Change
biotechnology
Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?
by Ekta Bagri
Liquidia's Yutrepia is driving strong growth, but Insmed's Brinsupri and broader pipeline could make it the better long-term pick.
INSMNegative Net Change LQDANegative Net Change
biotechnology biotechs medical pharmaceuticals
SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study
by Zacks Equity Research
Summit gains as positive HARMONi-GI1 data show ivonescimab's OS benefit in biliary tract cancer, expanding its potential beyond NSCLC.
SMMTNegative Net Change AZNNegative Net Change MRKNegative Net Change
biotechnology
AZN/AMGN's Tezspire Hits Primary Goal in Eosinophilic Esophagitis Study
by Zacks Equity Research
AstraZeneca's Tezspire delivers positive CROSSING data in EoE, meeting all primary and secondary endpoints and supporting its expansion potential.
AZNNegative Net Change AMGNNegative Net Change ACIUNegative Net Change AMRXNegative Net Change
biotechnology
Can Camzyos' Growth Offset Bristol Myers' Patent Pressures?
by Ekta Bagri
BMY's Camzyos gains momentum as an adolescent expansion nears an FDA decision, while rivals advance competing heart drugs.
BMYNegative Net Change CYTKNegative Net Change EWTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Arcturus Therapeutics (ARCT) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
ARCTNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program
by Zacks Equity Research
Biohaven stock rallies 18% on a $795M out-licensing deal granting SK Biopharmaceuticals global rights to its Kv7 epilepsy platform, led by opakalim.
BHVNNegative Net Change ACIUNegative Net Change AMRXNegative Net Change PGENNegative Net Change
biotechnology biotechs medical pharmaceuticals